1. Name and Address of Reporting Person
   JOHNSON & JOHNSON
   
   (Last)  (First)  (Middle)
   ONE JOHNSON & JOHNSON PLAZA
   
   (Street)  (City)  (State)  (Zip)
   NEW BRUNSWICK NJ 08933

2. Name and Ticker or Trading Symbol
   Fusion Pharmaceuticals Inc. [ FUSN ]

3. Date of Earliest Transaction (Month/Day/Year)
   06/30/2020

4. If Amendment, Date of Original Filed (Month/Day/Year)
   06/30/2020

5. Relationship of Reporting Person(s) to Issuer
   Director  X 10% Owner
   Officer (give title below)  Other (specify below)

6. Individual or Joint/Group Filing (Check Applicable Line)
   X Form filed by One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

<table>
<thead>
<tr>
<th>1. Title of Security (Instr. 3)</th>
<th>2. Transaction Date (Month/Day/Year)</th>
<th>3A. Deemed Execution Date, If any (Month/Day/Year)</th>
<th>4. Transaction Code (Instr. 8)</th>
<th>5. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)</th>
<th>6. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)</th>
<th>7. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)</th>
<th>7. Nature of Indirect Beneficial Ownership (Instr. 4)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Common Shares</td>
<td>06/30/2020</td>
<td></td>
<td>C</td>
<td>2,945,516</td>
<td>I</td>
<td>By Johnson &amp; Johnson Innovation - JJDC, Inc.(2)</td>
<td></td>
</tr>
<tr>
<td>Common Shares</td>
<td>06/30/2020</td>
<td></td>
<td>P</td>
<td>725,000 $17</td>
<td>I</td>
<td>By Johnson &amp; Johnson Innovation - JJDC, Inc.(2)</td>
<td></td>
</tr>
</tbody>
</table>

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

<table>
<thead>
<tr>
<th>1. Title of Derivative Security (Instr. 3)</th>
<th>2. Conversion or Exercise Price of Derivative Security</th>
<th>3. Transaction Date (Month/Day/Year)</th>
<th>4. Transaction Code (Instr. 8)</th>
<th>5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)</th>
<th>6. Date Exercisable (Month/Day/Year)</th>
<th>7. Title or Last Sale Price of Underlying Security (Instr. 3 and 4)</th>
<th>8. Price of Derivative Security (Instr. 9)</th>
<th>9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)</th>
<th>10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)</th>
<th>11. Nature of Indirect Beneficial Ownership (Instr. 4)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Class A Preferred Shares</td>
<td>(3)</td>
<td>06/30/2020</td>
<td>C</td>
<td>10,666,667 (3)</td>
<td>1,997,876</td>
<td>$0</td>
<td>0</td>
<td>1</td>
<td>By Johnson &amp; Johnson Innovation - JJDC, Inc.(2)</td>
<td></td>
</tr>
<tr>
<td>Class B Preferred Shares</td>
<td>(3)</td>
<td>06/30/2020</td>
<td>C</td>
<td>5,059,490 (3)</td>
<td>947,640</td>
<td>$0</td>
<td>0</td>
<td>1</td>
<td>By Johnson &amp; Johnson Innovation - JJDC, Inc.(2)</td>
<td></td>
</tr>
<tr>
<td>Warrants to purchase Class A Preferred Shares</td>
<td>(3)</td>
<td>06/30/2020</td>
<td>C</td>
<td>475,802 (3)</td>
<td>475,802</td>
<td>$0</td>
<td>0</td>
<td>1</td>
<td>By Johnson &amp; Johnson Innovation - JJDC, Inc.(2)</td>
<td></td>
</tr>
<tr>
<td>Warrants to purchase Class B Preferred Shares</td>
<td>(3)</td>
<td>06/30/2020</td>
<td>C</td>
<td>89,118 (3)</td>
<td>89,118</td>
<td>$0</td>
<td>89,118</td>
<td>1</td>
<td>By Johnson &amp; Johnson Innovation - JJDC, Inc.(2)</td>
<td></td>
</tr>
</tbody>
</table>

1. Name and Address of Reporting Person
   JOHNSON & JOHNSON
   
   (Last)  (First)  (Middle)
   ONE JOHNSON & JOHNSON PLAZA
   
   (Street)  (City)  (State)  (Zip)
   NEW BRUNSWICK NJ 08933

1. Name and Address of Reporting Person
   Johnson & Johnson Innovation - JJDC, Inc.
Explanation of Responses:

1. The Class A Preferred Shares and Class B Preferred Shares automatically converted into Common Shares on a 1-for-5.339 basis upon the closing of the Issuer's initial public offering, for no additional consideration. The Preferred Shares had no expiration date.

2. The securities reported as being indirectly beneficially owned by the designated Reporting Person are directly beneficially owned by Johnson & Johnson Innovation - JJDC, Inc., a wholly-owned subsidiary of the designated Reporting Person.

3. Upon the closing of the Issuer's initial public offering, the Warrants to purchase Class B Preferred Shares converted to Warrants to purchase Common Shares at an exercise price of $8.10 per share.

Remarks:

/s/ Matthew Orlando, Secretary of Johnson & Johnson 07/02/2020

/s/ Kevin Norman, Assistant Secretary of Johnson & Johnson Innovation - JJDC, Inc. 07/02/2020

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).


Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.